LISTEN: Why fatty livers are a pharma goldmine, a guide to ASCO and BIO, and Trump's latest drug price promise


s the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a discussion of NASH, the purported billion-dollar market opportunity that might be too good to be true, followed by a breakdown of a pair of upcoming conferences — one packed with news and the other not so much. Then comes a lightning round that touches on President Trump’s vague promises, the mystery surrounding a genomics pioneer, and drugs that make you racist.

For more on what we discuss, here’s the latest on NASH, and here’s a breakdown of BIO.


We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at

Source link

Leave a Reply

Your email address will not be published.